01:08:11 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2025-02-14 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-17 Kvartalsrapport 2024-Q1
2024-03-01 Ordinarie utdelning CSMED 0.00 DKK
2024-02-29 Årsstämma 2024
2024-02-14 Bokslutskommuniké 2023
2023-12-15 Ordinarie utdelning CSMED 0.00 DKK
2023-07-18 Kvartalsrapport 2023-Q3
2023-05-17 Kvartalsrapport 2023-Q2
2023-04-14 Extra Bolagsstämma 2023
2023-02-17 Kvartalsrapport 2023-Q1
2023-02-14 Årsstämma 2023
2023-02-10 Ordinarie utdelning CSMED 0.00 DKK
2022-11-18 Bokslutskommuniké 2022
2022-08-13 Kvartalsrapport 2022-Q3
2022-05-20 Kvartalsrapport 2022-Q2
2022-02-18 Kvartalsrapport 2022-Q1
2021-12-10 Ordinarie utdelning CSMED 0.00 DKK
2021-12-09 Årsstämma 2022
2021-11-18 Bokslutskommuniké 2021


ListaSpotlight DK
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2023-06-15 13:26:35

CS MEDICA, Pioneering the Transition to MDR, Sign Contract with a Notified Body in Europe, Safeguarding Their Medical Device Product Line's Market Presence

CS MEDICA A/S ("CS MEDICA" or "The Company"), a global MedTech company specializing in relieving symptoms of autoimmune diseases and stress-related disorders, is a first mover of CE-marked medical devices with CBD in the MDR (Medical Device Regulation[1]) transition grace period until 2028. 

The Company's competitive advantage has been strengthened as CS MEDICA now secured its position by being one of the first companies in the European Union to sign with a Notified Body, to fulfill the required steps under Rule 21[2] toward compliance with the new regulations.

"We are proud to announce CS MEDICA signed with the Notified Body in the Netherlands, which can help us secure the transition to MDR and is to issue the CE MDR certificate for the products. This achievement showcases our dedication to maintaining the utmost quality and safety in our products, while also demonstrating our commitment to meeting the rigorous requirements set forth by the New MDR regulation", states Lone Henriksen, CEO and co-founder, CS MEDICA A/S. 

Lone continues; "It is further a true cornerstone for our company's global growth plans, especially partnering with Big Pharma players and positioning our company closer to the medicine industry long-term." 


[1] About MDR - Read more from public references as: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32023R0607 or https://medicoindustrien.dk/article/nyt-om-mdr-udsaettelse-af-overgangsfase-mdr-stemt-igennem-af-eu-parlamentet  or https://www.greenlight.guru/blog/questions-about-european-mdr-answered

[2] The EU-MDR Rule 21 - devices composed of substances or of combinations of substances to be introduced into the human body via a body orifice or applied to the skin and absorbed by or locally dispersed in the human body. Impacted manufacturers are seeing their products up classified to Class IIb shifting their regulatory requirements, in some cases, from self-declared Class I to full conformity assessment procedures with notified body involvement. Reference: https://health.ec.europa.eu/system/files/2021-10/mdcg_2021-24_en_0.pdf

This disclosure contains information that CS MEDICA A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 15-06-2023 13:26 CET.